

Review Article

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges

Erica di Martino,¹ Darren C. Tomlinson,² and Margaret A. Knowles¹

¹ Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds LS9 7TF, UK

² Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK

Correspondence should be addressed to Erica di Martino, e.dimartino@leeds.ac.uk

Received 31 May 2012; Accepted 17 June 2012

Academic Editor: Nan-Haw Chow

Copyright © 2012 Erica di Martino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFRs) and activating downstream signalling pathways, including RAS/MAPK, PLC γ 1, PI3K, and STATs. In the last ten years, it has become clear that FGF signalling is altered in a high proportion of bladder tumours. Activating mutations and/or overexpression of *FGFR3* are common in urothelial tumours with low malignant potential and low-stage and -grade urothelial carcinomas (UCs) and are associated with a lower risk of progression and better survival in some subgroups. *FGFR1* is not mutated in UC, but overexpression is frequent in all grades and stages and recent data indicate a role in urothelial epithelial-mesenchymal transition. *In vitro* and *in vivo* studies have shown that FGFR inhibition has cytotoxic and/or cytostatic effects in FGFR-dependent bladder cancer cells and FGFR-targeted agents are currently being investigated in clinical studies for the treatment of UC. Urine-based tests detecting common *FGFR3* mutations are also under development for surveillance of low-grade and -stage tumours and for general population screening. Overall, FGFRs hold promise as therapeutic targets, diagnostic and prognostic markers, and screening tools for early detection and clinical management of UC.

1. Urothelial Carcinoma: Clinical Management and Challenges

Bladder cancer is a common malignancy with over 70,000 estimated new cases and 14,000 deaths per year in the USA alone [1]. In western countries, around 90% of bladder tumours are transitional cell carcinoma, with rare cases of squamous cell carcinoma and adenocarcinoma [2]. Bladder tumours are classified using the TNM classification system [3] according to their invasiveness (stage Ta: confined to the urothelium; T1: invading the lamina propria; T2: invading the muscular layer; T3: invading the submuscular layers; T4: disseminating to other organs) and their differentiation state (1973 WHO grading system: grade 1, 2, or 3 [4]; 2004 WHO grading system: PUNLMP: papillary urothelial neoplasm of low-malignant potential, low grade: well-differentiated neoplasms, high grade: poorly differentiated neoplasms [2]). At presentation, the vast majority of urothelial carcinomas (UC) (~70%) are low-grade superficial papillary tumours

with a relatively benign prognosis. Their conventional treatment involves surgical resection and intravesical chemo- or immunotherapy [5]. One of the major challenges in the management of these tumours is their propensity to recur, therefore requiring frequent and often life-long surveillance with cystoscopy and urine cytology. This, coupled with a relatively long life expectancy (5-year survival rate >90%), makes superficial bladder cancer the most expensive and time-consuming malignancy to treat [6, 7]. A minority of superficial tumours (~15%) will eventually progress to become invasive. Despite treatment with radical cystectomy, radiotherapy, and adjuvant or neoadjuvant chemotherapy, newly diagnosed invasive bladder tumours and superficial tumours that have progressed to invasion often metastasize and the 5-year survival rate is poor (<40%) [8].

Currently there are no validated prognostic molecular biomarkers to guide the clinical management of UC. Crucial therapeutic decisions are based on risk tables that include tumour size and number, and previous history [9], in

addition to histopathological criteria, which are often limited by inter- and intraobserver variability and have relatively low reproducibility [10, 11]. Overall, UC management would greatly benefit from rapid cost-effective and noninvasive methods for screening and surveillance, and reproducible and objective molecular biomarkers to predict the risks of recurrence and progression so that more aggressive therapeutic regimes and intensive monitoring could be focussed on patients at higher risk. Furthermore, novel therapeutic approaches and related predictive biomarkers are needed, for use alone or in combination with conventional treatment, to reduce recurrence rate and progression of superficial tumours and prolong survival and quality of life in patients with invasive and metastatic tumours.

2. Structure and Function of Fibroblast Growth Factor Receptors

In humans, fibroblast growth factors are a family comprising 18 growth factors (FGFs) and 4 FGF-homologous factors (FHF), many of which play a crucial role during both normal physiological processes, such as embryogenesis, development, and wound healing, and a range of pathological conditions [12–14]. The effects of FGFs are mediated by a family of four fibroblast growth factor receptors (FGFR1–4). FGFRs are transmembrane glycoproteins with a conserved structure comprising an extracellular portion with two to three immunoglobulin-like domains (IgI–III), a transmembrane domain, and an intracellular split tyrosine-kinase domain. IgI and IgII are separated by a short negatively charged serine-rich segment, termed the “acid box”, followed by a heparin-binding domain with high affinity for heparan sulphate proteoglycans (HSPGs) [12, 13]. IgI and the acid box are thought to have an auto-inhibitory function [15], while IgII and IgIII bind to FGFs in association with HSPGs. FGF binding to the monomeric receptor triggers its dimerization and subsequent transphosphorylation of tyrosine residues in the kinase domain. This initiates a phosphorylation cascade involving a number of docking proteins, resulting in signalling through various downstream pathways, including PLC γ 1, RAS-MAPK, and PI3K and STATs [16]. These pathways regulate a variety of cellular functions, including proliferation, migration, and differentiation [16].

Affinity for specific FGFs varies between receptors [17, 18] and a further layer of complexity is added by the fact that FGFRs are subject to alternative splicing, generating isoforms with different ligand-binding specificity in different cell lineages. For example, two alternative isoforms of FGFR3, denoted “b” and “c” are produced by mutually exclusive splicing of exon 8 and exon 9, affecting IgIII [19]. FGFR3b is expressed in epithelial cells and has high affinity only for FGF1. FGFR3c is expressed in cells of mesenchymal origin and has affinity for FGF1, FGF2, FGF4, and other FGFs [17, 19]. Similarly, an alternative FGFR1 isoform, denoted FGFR1 β , lacking the IgI domain and with increased affinity to FGF1 and heparin compared to FGFR1 α , has been described [20]. Secreted isoforms of FGFRs have also been reported [21, 22].

A fifth FGF receptor has been described [23]. FGFR5 is homologous to the other four receptors in the extracellular portion, but lacks the tyrosine-kinase domain, which is replaced by a short histidine-rich sequence. FGFR5 is therefore regarded as a decoy receptor, which can inhibit signalling by binding and sequestering FGFs [24].

3. Aberrant FGF Signalling in Urothelial Malignancies

3.1. FGFR3 Alterations in Urothelial Tumours

3.1.1. Activating Mutations. Somatic activating mutations of *FGFR3* were first described in UC over ten years ago [25, 26]. Subsequent larger studies established that *FGFR3* mutations occur in around 50% of both lower and upper urinary tract tumours and these cluster in three distinct hotspots in exons 7, 10, and 15 [27–32] (Figure 1). The most common mutations in exon 7 and 10 are S249C (~61%), Y375C (~19%), R248C (~8%), and G372C (~6%), with others occurring at very low frequencies (<2%). Mutations in exon 7 and 10 create a cysteine or glutamic acid residue in the proximal extracellular region of the receptor. The abnormal residues form either disulfide or hydrogen bonds between adjacent monomer receptors, favouring ligand-independent dimerization, transactivation, and signalling [33–35]. Mutations in exon 15 are rarer, with a frequency of around 2%, and they all involve the lysine residue at position 652, which is mutated to glutamic acid, glutamine, threonine or methionine. They are thought to induce a conformational change in the kinase domain resulting in ligand-independent receptor activation and signalling [36]. They have also been shown to alter FGFR3 cellular localization, inducing aberrant signalling from the endoplasmic reticulum [37].

FGFR3 mutations are frequent in benign skin tumours [43] and have been reported at low frequency in cervical carcinoma [25] and multiple myeloma [44], but are absent in other solid cancers [45, 46], suggesting a tissue-specific role. Interestingly, the relative frequency of different *FGFR3* mutations is dependent on the tumour type, with multiple myeloma mostly showing changes in the tyrosine-kinase domain [44], and bladder and cervical tumours mainly exhibiting mutations of the extracellular region. Furthermore, while S249C is by far the most frequent mutation in bladder (Figure 1) and cervical tumours [25], mutation of the adjacent codon (R248C) is the commonest change found in benign skin tumours [43]. It is currently unclear whether the spectrum, frequency and tissue specificity of *FGFR3* mutations is determined by exposure to specific carcinogens or by their functional significance. The role of smoking and occupational exposure to polycyclic aromatic hydrocarbons in determining the frequency or the type of *FGFR3* mutations in UC has been excluded [47, 48]. However, the limited range of hotspot codons in the receptor makes this a difficult target to study from the epidemiological viewpoint and the possibility of small influences of these exposures cannot be excluded without much larger studies. We have recently shown a correlation between the level of ligand




FIGURE 1: Schematic representation of human *FGFR3* protein and corresponding *FGFR3* coding exons. Exon numbering based on Tomlinson et al. [38]. Type and total number of reported mutations are based on data pooled from 11 studies [25–29, 31, 32, 39–42], including a total of 1898 bladder tumours. SP: signal peptide; IgI–III: immunoglobulin-like domain; AB: acid box; TM: transmembrane domain; TK; tyrosine-kinase domain.

independence, signalling activation, and phenotypic consequences of different *FGFR3* mutations expressed in normal urothelial cells and their frequency in UC, suggesting that the spectrum of *FGFR3* mutations in bladder tumours may relate to selection for their potency [49]. We also highlighted cell-type-dependent phenotypic and signalling consequences of specific *FGFR3* mutations which may explain the differences in the relative frequencies between tumour types [49].

During urothelial transformation, *FGFR3* mutations are thought to occur early, as they are reported in flat urothelial hyperplasia, a preneoplastic lesion [50]. Furthermore, *FGFR3* mutations are extremely common in the most benign bladder lesions (low malignant potential neoplasms and urothelial papillomas) and low-grade and -stage tumours (PUNLMP; TaG1), reaching frequencies over 80% in these subgroups [27, 28, 39]. This evidence points to an overall “benign” effect of *FGFR3* mutation in the bladder. Interestingly, all somatic mutations reported so far in UC have been previously described as germline mutations in skeletal dysplasia syndromes, due to the important role of *FGFR3* in regulating chondrocyte proliferation and differentiation [51].

3.1.2. Overexpression and Alternative Splicing. Overexpression of wild-type *FGFR3* due to t(4; 14) translocation, which places *FGFR3* in the proximity of the regulatory region of the IgH locus, is common in multiple myeloma [44]. Such rearrangements have not been described in bladder cancer. However several reports have examined *FGFR3* protein expression in bladder carcinomas, describing an increase in a high proportion of tumours, particularly in the low-grade and low-stage subgroups [32, 40, 52–54]. Two recent investigations have examined the correlation between mutation status and protein expression, showing that up to 85% of the mutated tumours also have increased protein levels [32, 40]. Overexpression of *FGFR3* was also detected in around

40% of wild-type tumours, and this was more common in invasive cases. Overall, around 80% of non-invasive and 54% of invasive UC have dysregulated *FGFR3* either through mutation, overexpression or both [32]. Therefore, *FGFR3* plays a key role in both superficial and invasive disease. However, while superficial tumours tend to exhibit activating mutations of *FGFR3*, often accompanied by protein upregulation, invasive tumours more commonly show upregulation of wild-type *FGFR3*. At this stage, it is not clear whether this difference reflects differential downstream signalling consequences of wild-type and mutant receptors or the different molecular pathways through which these tumours develop. The molecular mechanisms driving *FGFR3* protein overexpression in UC are also still largely unknown, although a recent study has shown that *FGFR3* expression in urothelial cells is regulated by two microRNAs (miR-99a/100), which are often downregulated in UC, particularly in low-grade and low-stage tumours [55].

Overexpressed *FGFR3* could contribute to tumour development by either ligand-dependent or independent mechanisms. FGF levels are often increased in urine and tumour tissue of bladder cancer patients [56, 57]. Parallel overexpression of FGFs and FGFRs could therefore result in upregulated FGF signalling. It is also speculated that overexpression of the wild-type receptor may favour ligand-independent dimerization and signalling due to the close physical proximity of *FGFR3* monomers on the cell surface. Overexpression of *FGFR3* would be particularly deleterious if accompanied by a switch to alternative isoforms with different FGF affinity profiles, which would allow tumour cells to activate FGF signalling in response to a greater number of substrates. A switch from the epithelial *FGFR3b* to the mesenchymal *FGFR3c* isoform, with broader ligand affinity has been described in bladder cancer cell lines [38]. However, as *FGFR3c* was not detected in a panel of 76 bladder carcinoma [25], the role of *FGFR3* isoform switching in UC *in vivo* is




FIGURE 2: Mechanisms of physiological (a)-(b) and pathological (c)-(f) activation of FGFR3. (a) Monomeric inactive receptor; (b) Ligand-dependent dimerization and activation; (c) Ligand-independent dimerization and activation induced by mutation of the extracellular portion; (d) Ligand-independent activation due to mutations of the tyrosine-kinase domain; (e) Upregulation of signalling due to receptor overexpression; (f) Alteration of splicing favouring isoforms with broader ligand specificity.

still unclear. The different mechanisms of FGFR3 abnormal activation in bladder cancer are summarized in Figure 2.

3.2. FGFR1 Alterations in Urothelial Tumours. In many malignancies FGFR1 has been implicated as an oncogene whose expression or genetic arrangement is altered compared to normal tissue [58–63]. In mouse models of prostate and breast carcinoma, FGFR1 activation *via* an inducible regulation system accelerated progression to malignancy [64–67]. Furthermore, FGFR1 signaling was shown to contribute to the survival of a breast cancer cell line, indicating FGFR1 as potential therapeutic target [63]. More, recently it has been shown that FGFR1 is overexpressed in bladder cancer [68]. Interestingly, FGFR1 expression was increased in both noninvasive and invasive tumours. In light of the changes in FGFR3 splicing observed in UC cell lines [38], FGFR1 splicing was examined. This revealed an altered ratio of FGFR1 α and β splice variants, with increased expression of the β isoform, lacking the IgI domain. The increased expression of this splice variant was significantly associated with tumour stage and grade and caused an increased sensitivity to FGF1 and enhanced downstream signalling [69]. Overall these studies demonstrate that FGFR1, *via* overexpression or altered splicing, may play a key role during bladder tumour development and/or progression.

3.3. Other FGFRs. In contrast to FGFR3 and FGFR1, FGFR2 appears to have a protective or tumour-suppressor role in bladder cancer. Its expression is downregulated in UC and low levels are associated with worse prognosis [70]. Furthermore, FGFR2 re-expression in a UC cell line was associated with reduced proliferation *in vitro* and diminished tumorigenicity in nude mice [71]. No evidence is available regarding FGFR4 and FGFR5 in UC.

3.4. Phenotypic Consequences of Upregulated FGF Signalling in Urothelial Cells. Few studies have investigated the effects of FGFR dysregulation in normal and malignant urothelial

cells. Knockdown or inhibition of FGFR3 signalling in the FGFR3-mutant UC cell lines MGHU3 (Y375C), 97-7 (S249C) and UMUC14 (S249C) is accompanied by diminished cell proliferation and/or anchorage dependent growth *in vitro* in all, although with different efficacy [72–75]. Tumorigenic potential *in vivo* is also reduced [72, 74]. Similar effects were seen in UC cell lines RT112 and RT4, which overexpress FGFR3 with no detectable point mutations [74]. These results show that some UC, both FGFR3-mutant and wild-type, have “oncogene addiction” to FGFR3. In contrast, knockdown of FGFR1 in the FGFR1-overexpressing invasive UC cell line UMUC3 did not affect proliferation *in vitro* despite a clear effect on anchorage independent growth and tumorigenicity *in vivo* [68].

Our group has recently begun to elucidate the specific phenotypic differences between FGFR1 and FGFR3 activation in urothelial cells. When mutant FGFR3 was overexpressed in normal urothelial cells, subtle phenotypic changes were observed. The cells had a higher proliferative rate and reduced apoptosis only in confluent cultures, suggesting that activation of FGFR3 signalling may assist premalignant urothelial cells in overcoming cell-cell contact inhibition and favour the formation of hyperplastic bladder lesions [49]. These phenotypes are compatible with the hypothesis that *FGFR3* mutation contributes early in the process of tumour development. FGFR1 overexpression and activation, in contrast, has a more profound effect on proliferation and survival of normal urothelial cells, even in subconfluent culture conditions [68]. As expected, neither mutant FGFR3 or upregulated FGFR1 was sufficient alone to confer on normal urothelial cells a fully transformed phenotype, such as anchorage-independent growth or the ability to form tumours in nude mice [49, 68].

Our recent data, however, show that activation of overexpressed FGFR1 in bladder cancer cell lines is sufficient to induce an epithelial mesenchymal transition (EMT) [76]. EMT developed over a period of 72 hours. Initially a rapid increase in actin stress fibres occurred, followed by an increase in cell size, altered morphology and increased migration and invasion. By using site-directed mutagenesis and small molecule inhibitors, it was shown that combined activation of the mitogen-activated protein kinase (MAPK) and phospholipase C gamma (PLC γ) pathways regulated this EMT. Expression array analysis identified COX-2 as a major upregulated transcript following FGFR1 activation and this led to increased intracellular prostaglandin E₂ levels, which promoted migration. This suggests that the timing and cellular context of FGFR1 dysregulation may be crucial in determining its phenotypic consequences and may influence the development of either superficial or invasive bladder tumours.

Interestingly, despite driving different phenotypes, the signalling pathways activated by FGFR1 and FGFR3 in both normal and malignant cells are similar and involve FRS2, PLC γ 1 and ERK1/2 [49, 68]. These observations imply that context-specific downstream effectors of these signalling pathways and interaction with other molecular events need to be elucidated to fully understand the observed phenotypic differences.

4. Clinical Applications

The potential applications of FGFRs in the early diagnosis and clinical management of bladder cancer are summarized in Figure 3.

4.1. Surveillance and Screening. As mutations of *FGFR3* are found in up to 80% of primary Ta tumours, which are characterized by a high recurrence rate, detection of *FGFR3* mutations in urine is currently under study as a noninvasive and inexpensive method for the surveillance of superficial *FGFR3* mutation-positive bladder tumours. A test has been developed to detect eleven common *FGFR3* mutations by multiplex polymerase chain reaction amplification of the three hotspot regions followed by SNaPshot mutation analysis [77]. When applied to urine samples pooled within a 24-hr period, this test is able to detect all mutant tumours irrespective of their size [78]. However, overall sensitivity is around 80%, as it is limited by the fact that around one-fifth of patients with an *FGFR3*-mutant primary tumour have *FGFR3* wild-type recurrences [78, 79].

Detection of *FGFR3* mutations in urine could also be employed for general population screening aimed at early detection of primary tumours. Preliminary results show that a combined test for mutation of *FGFR3*, *PIK3CA* and *RAS* could potentially detect 75% of primary tumours, including 88% of the pTa-T1G1-2 tumours but only 36% of the high-grade and -stage malignancies [79]. Addition of other markers is being considered to improve detection of invasive tumours [80, 81].

4.2. Prognosis. *FGFR3* mutation status has been investigated as a prognostic marker for recurrence, progression, and survival. A small study including 53 pTaG1-2 tumours showed that wild-type *FGFR3* is predictive of disease recurrence [41]. In contrast, in a subsequent larger study of 764 superficial tumours *FGFR3* mutation was predictive of a higher rate of recurrence in TaG1 but not TaG3 or T1 tumours [28]. In this investigation, TaG2 tumours showed a trend towards a higher recurrence rate but did not reach statistical significance. Whilst an association between *FGFR3* mutation and risk of progression was not detected in this cohort, where progression rate was small [28], other studies suggested a negative correlation [30, 31, 82]. An international prospective study including 221 superficial tumours indicated that *FGFR3* status is not associated with recurrence but is predictive of disease progression in some subgroups (pT1 and high-grade malignancies) [30]. Inverse correlation between *FGFR3* mutation and progression in pT1 tumours was also confirmed in a subsequent investigation [83]. A multicentre study comprising 230 superficial tumours suggested that adding *FGFR3* mutation status and Ki-67 positivity to current histopathological criteria improved prediction of progression in about 7% of patients [84]. Furthermore, better survival rates were suggested for patients with muscle invasive tumours harbouring an *FGFR3* mutation [31]. In a recent study, *FGFR3* mutation status was found to be predictive of progression, recurrence, and outcome only when combined with 9p22 LOH status [85], but this was in a

relatively small sample set, including only 29 *FGFR3*-mutant tumours. Overall, further research is needed to confirm the utility of *FGFR3*-mutation status as molecular marker for patient stratification alongside current prognostic criteria.

4.3. FGFR-Targeted Therapy in Bladder Cancer. As *FGFR3* and *FGFR1* are altered in the majority of superficial tumours and in a good proportion of invasive tumours, they represent very inviting therapeutic targets. As discussed in paragraph 3.4, *in vitro* and *in vivo* studies using siRNA or shRNA knockdown or specific antibodies to block FGFRs activity have shown that some UC cell lines are *FGFR3*-dependent.

A number of *FGFR*-targeted therapeutic agents have been tested in bladder cancer cell lines *in vitro* and *in vivo*. PD173074 is a selective *FGFR*-inhibitor, which functions by competing with ATP binding and inhibiting autophosphorylation [86]. TKI258 and SU5402 are broader-profile inhibitors which target both *FGFRs* and *VEGFR* [87, 88]. All three compounds were found to be cytotoxic and/or cytostatic on a range of *FGFR3*- or *FGFR1*-dependent bladder cancer cell lines *in vitro* and to reduce *FGFR* phosphorylation and downstream signalling, with PD173074 and TKI258 showing the greatest effect [89, 90]. PD173074 had no toxicity on normal bladder cells, suggesting the existence of a useful therapeutic window, while TKI258 had some detrimental effects, perhaps due to its broader target range [90]. PD173074 was also tested *in vivo* on xenografts obtained from UMUC14, MGHU3, RT112, and SW780 cells and was shown to inhibit growth and induce tumour regression, although growth resumed following drug withdrawal [89, 90]. Notably, response to PD173074 appeared to be related to the level of *FGFR* expression and dependence, rather than to mutation status. Some *FGFR3*-mutant cell lines (J82, 94-10) were less sensitive than *FGFR3*-overexpressing cell lines (RT112, RT4, SW780) and other *FGFR3*-mutant cell lines (UMUC14, MGHU3, 97-7). Similarly, in *FGFR1*-overexpressing cell lines, treatment with PD173074 was effective in JMSU1 but not UMUC3, despite similar levels of *FGFR1* expression [68]. This may be attributable to the fact that UMUC3 cells also have a *KRAS2* mutation, which activates the same downstream pathways as *FGFR* signalling. Alternatively, it is possible that *FGFR*-dependence may confer an initial survival advantage on bladder cancer cells, which may later be replaced by other oncogenic events. There may therefore be an early “susceptibility window” during which tumours are treatable with *FGFR* inhibitors as single agents. Overall, the *in vivo* and *in vitro* studies confirm that *FGFR* inhibitors may be of clinical relevance in the treatment of bladder cancer but also raise some crucial issues, particularly the requirement for biomarkers of *FGFR* dependence to predict response to treatment and the need for combination therapy with other agents due to the likely recurrence and/or resistance after treatment withdrawal. Clinical studies currently underway with several *FGFR* inhibitors [91] are hoped to shed light on some of these issues.

FGFR-blocking antibodies represent an alternative approach to the use of small molecule inhibitors. Humanized and fully human synthetic antibodies have recently become available for therapeutic purposes and present several




FIGURE 3: Potential applications of FGFRs in the early detection and clinical management of bladder tumours.

advantages including low toxicity, high target specificity, easy tissue penetration, and the possibility to be combined with immunotoxins or radionucleotides for specific targeting to malignant cells [92]. Results so far are promising. For example, a single-chain Fv against FGFR3 conjugated to the gelonin toxin was shown to block proliferation and induce apoptosis of the FGFR3-overexpressing cell lines RT112 and RT4 both *in vivo* and *in vitro* [93].

The elucidation of downstream targets of FGFR signalling in bladder tumours could also open up new avenues for therapeutic intervention. For example, the discovery that FGFR1 may drive EMT through COX-2 activation [76] suggests that COX-2 inhibition may be particularly beneficial in FGFR1-dependent invasive tumours. A clinical trial utilising a COX-2 inhibitor is currently in progress and it would be interesting to see whether the clinical outcomes correlate with FGFR1 expression and activation levels.

5. Conclusions

In the last decade, it has become clear that FGFRs play a key role in the development of UC and hold promise as therapeutic targets, screening tools, and diagnostic, and prognostic

biomarkers. Future challenges include detailed elucidation of downstream signalling, refining FGFR-based screening and prognostic tests, identification of markers to select patients most likely to benefit from FGFR-targeted therapies and development of strategies to overcome recurrence after treatment withdrawal or development of resistance. There is great hope that in the near future the results of research on the role of FGFRs in UC will be translated into the clinical management of these tumours.

References

- [1] A. Jemal, R. Siegel, J. Xu, and E. Ward, "Cancer statistics, 2010," *Cancer Journal for Clinicians*, vol. 60, no. 5, pp. 277–300, 2010.
- [2] J. N. S. G. Eble, J. I. Epstein, and I. A. Sesterhenn, Eds., *Editor-World Health Organization. Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, IARC Press, Lyon, France, 2004.
- [3] L. H. Sobin, M. K. Gospodarowicz, and C. Wittekind, *TNM Classification of Malignant Tumours*, Wiley-Blackwell, Oxford, UK, 2010.

- [4] F. K. Mostofi, C. J. Davies, and I. Sesterhenn, *Histological Typing of Urinary Bladder Tumours*, Springer, New York, NY, USA, 1999.
- [5] M. Brausi, J. A. Witjes, D. Lamm, R. Persad, J. Palou et al., "A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group," *The Journal of Urology*, vol. 186, no. 6, pp. 2158–2167, 2011.
- [6] M. F. Botteman, C. L. Pashos, A. Redaelli, B. Laskin, and R. Hauser, "The health economics of bladder cancer: a comprehensive review of the published literature," *Pharmacoeconomics*, vol. 21, no. 18, pp. 1315–1330, 2003.
- [7] V. K. Sangar, N. Ragavan, S. S. Matanhelia, M. W. Watson, and R. A. Blades, "The economic consequences of prostate and bladder cancer in the UK," *BJU International*, vol. 95, no. 1, pp. 59–63, 2005.
- [8] C. L. Pashos, M. F. Botteman, B. L. Laskin, and A. Redaelli, "Bladder cancer: epidemiology, diagnosis, and management," *Cancer Practice*, vol. 10, no. 6, pp. 311–322, 2002.
- [9] R. J. Sylvester, A. P. M. van der Meijden, W. Oosterlinck et al., "Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials," *European Urology*, vol. 49, no. 3, pp. 466–475, 2006.
- [10] J. A. Witjes, L. A. L. M. Kiemeny, H. E. Schaafsma, and F. M. J. Debruyne, "The influence of review pathology on study outcome of a randomized multicentre bladder cancer trial," *British Journal of Urology*, vol. 73, no. 2, pp. 172–176, 1994.
- [11] I. Tosoni, U. Wagner, G. Sauter et al., "Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer," *BJU International*, vol. 85, no. 1, pp. 48–53, 2000.
- [12] R. T. Böttcher and C. Niehrs, "Fibroblast growth factor signaling during early vertebrate development," *Endocrine Reviews*, vol. 26, no. 1, pp. 63–77, 2005.
- [13] C. J. Powers, S. W. McLeskey, and A. Wellstein, "Fibroblast growth factors, their receptors and signaling," *Endocrine-Related Cancer*, vol. 7, no. 3, pp. 165–197, 2000.
- [14] A. Beenken and M. Mohammadi, "The FGF family: biology, pathophysiology and therapy," *Nature Reviews Drug Discovery*, vol. 8, no. 3, pp. 235–253, 2009.
- [15] S. K. Olsen, O. A. Ibrahimi, A. Raucci et al., "Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 4, pp. 935–940, 2004.
- [16] P. Klint and L. Claesson-Welsh, "Signal transduction by fibroblast growth factor receptors," *Frontiers in Bioscience*, vol. 4, pp. D165–D177, 1999.
- [17] D. M. Ornitz, J. Xu, J. S. Colvin et al., "Receptor specificity of the fibroblast growth factor family," *The Journal of Biological Chemistry*, vol. 271, no. 25, pp. 15292–15297, 1996.
- [18] X. Zhang, O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi, and D. M. Ornitz, "Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family," *The Journal of Biological Chemistry*, vol. 281, no. 23, pp. 15694–15700, 2006.
- [19] A. T. Chelliah, D. G. McEwen, S. Werner, J. Xu, and D. M. Ornitz, "Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1," *The Journal of Biological Chemistry*, vol. 269, no. 15, pp. 11620–11627, 1994.
- [20] F. Wang, M. Kan, G. Yan, J. Xu, and W. L. McKeehan, "Alternatively spliced NH₂-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1," *The Journal of Biological Chemistry*, vol. 270, no. 17, pp. 10231–10235, 1995.
- [21] L. L. Root and G. D. Shipley, "Normal human fibroblasts produce membrane-bound and soluble isoforms of FGFR-1," *Molecular Cell Biology Research Communications*, vol. 3, no. 2, pp. 87–97, 2000.
- [22] M. Terada, A. Shimizu, N. Sato, S. I. Miyakaze, H. Katayama, and M. Kurokawa-Seo, "Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs," *Molecular Cell Biology Research Communications*, vol. 4, no. 6, pp. 365–373, 2001.
- [23] M. Sleeman, J. Fraser, M. McDonald et al., "Identification of a new fibroblast growth factor receptor, FGFR5," *Gene*, vol. 271, no. 2, pp. 171–182, 2001.
- [24] B. Trueb, "Biology of FGFR1, the fifth fibroblast growth factor receptor," *Cellular and Molecular Life Sciences*, vol. 68, no. 6, pp. 951–964, 2011.
- [25] J. Bourdin, X. Sastre-Garau, D. Chopin, J. P. Thiery, and F. Radvanyi, "Frequent activating mutations of *FGFR3* in human bladder and cervix carcinomas," *Nature Genetics*, vol. 23, no. 1, pp. 18–20, 1999.
- [26] K. Sibley, D. Cuthbert-Heavens, and M. A. Knowles, "Loss of heterozygosity at 4p16.3 and mutation of *FGFR3* in transitional cell carcinoma," *Oncogene*, vol. 20, no. 6, pp. 686–691, 2001.
- [27] B. W. G. van Rhijn, R. Montironi, E. C. Zwarthoff, A. C. Jöbsis, and T. H. van der Kwast, "Frequent *FGFR3* mutations in urothelial papilloma," *The Journal of Pathology*, vol. 198, no. 2, pp. 245–251, 2002.
- [28] S. Hernández, E. López-Knowles, J. Lloreta et al., "Prospective study of *FGFR3* mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas," *Journal of Clinical Oncology*, vol. 24, no. 22, pp. 3664–3671, 2006.
- [29] C. Billerey, D. Chopin, M. H. Aubriot-Lorton et al., "Frequent *FGFR3* mutations in papillary non-invasive bladder (pTa) tumors," *American The Journal of Pathology*, vol. 158, no. 6, pp. 1955–1959, 2001.
- [30] M. Burger, M. N. M. van der Aa, J. M. M. van Oers et al., "Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by *FGFR3* mutation status: a prospective study," *European Urology*, vol. 54, no. 4, pp. 835–844, 2008.
- [31] J. M. M. van Oers, E. C. Zwarthoff, I. Rehman et al., "*FGFR3* mutations indicate better survival in invasive upper urinary tract and bladder tumours," *European Urology*, vol. 55, no. 3, pp. 650–658, 2009.
- [32] D. C. Tomlinson, O. Baldo, P. Hamden, and M. A. Knowles, "*FGFR3* protein expression and its relationship to mutation status and prognostic variables in bladder cancer," *The Journal of Pathology*, vol. 213, no. 1, pp. 91–98, 2007.
- [33] R. Adar, E. Monsonego-Ornan, P. David, and A. Yayon, "Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization," *Journal of Bone and Mineral Research*, vol. 17, no. 5, pp. 860–868, 2002.
- [34] P. Y. D'Avis, S. C. Robertson, A. N. Meyer, W. M. Bardwell, M. K. Webster, and D. J. Donoghue, "Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I," *Cell Growth and Differentiation*, vol. 9, no. 1, pp. 71–78, 1998.

- [35] F. Chen, C. Degin, M. Laederich, W. A. Horton, and K. Hristova, "The A391E mutation enhances *FGFR3* activation in the absence of ligand," *Biochimica et Biophysica Acta*, vol. 1808, no. 8, pp. 2045–2050, 2011.
- [36] M. K. Webster, P. Y. D'Avis, S. C. Robertson, and D. J. Donoghue, "Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II," *Molecular and Cellular Biology*, vol. 16, no. 8, pp. 4081–4087, 1996.
- [37] P. M. J. Lievens, A. Roncador, and E. Liboi, "K644E/M *FGFR3* mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 α and PLC γ -independent pathways," *Journal of Molecular Biology*, vol. 357, no. 3, pp. 783–792, 2006.
- [38] D. C. Tomlinson, C. G. L'Hôte, W. Kennedy, E. Pitt, and M. A. Knowles, "Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines," *Cancer Research*, vol. 65, no. 22, pp. 10441–10449, 2005.
- [39] T. Kimura, H. Suzuki, T. Ohashi, K. Asano, H. Kiyota et al., "The incidence of thanatophoric dysplasia mutations in *FGFR3* gene is higher in low-grade or superficial bladder carcinomas," *Cancer*, vol. 92, no. 10, pp. 2555–2561, 2001.
- [40] K. Bodoor, A. Ghabkari, Z. Jaradat et al., "*FGFR3* mutational status and protein expression in patients with bladder cancer in a Jordanian population," *Cancer Epidemiology*, vol. 34, no. 6, pp. 724–732, 2010.
- [41] B. W. G. van Rhijn, I. Lurkin, F. Radvanyi, W. J. Kirkels, T. H. van der Kwast, and E. C. Zwarthoff, "The fibroblast growth factor receptor 3 (*FGFR3*) mutation is a strong indicator of superficial bladder cancer with low recurrence rate," *Cancer Research*, vol. 61, no. 4, pp. 1265–1268, 2001.
- [42] B. van Rhijn, A. van Tilborg, I. Lurkin et al., "Novel fibroblast growth factor receptor 3 (*FGFR3*) mutations in bladder cancer previously identified in non-lethal skeletal disorders," *European Journal of Human Genetics*, vol. 10, no. 12, pp. 819–824, 2002.
- [43] C. Hafner, J. M. M. Van Oers, A. Hartmann et al., "High frequency of *FGFR3* mutations in adenoid seborrhic keratoses," *Journal of Investigative Dermatology*, vol. 126, no. 11, pp. 2404–2407, 2006.
- [44] M. Chesi, E. Nardini, L. A. Brents et al., "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3," *Nature Genetics*, vol. 16, no. 3, pp. 260–264, 1997.
- [45] M. Karoui, H. Hofmann-Radvanyi, U. Zimmermann et al., "No evidence of somatic *FGFR3* mutation in various types of carcinoma," *Oncogene*, vol. 20, no. 36, pp. 5059–5061, 2001.
- [46] K. Sibley, P. Stern, and M. A. Knowles, "Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours," *Oncogene*, vol. 20, no. 32, pp. 4416–4418, 2001.
- [47] H. Wallerand, A. A. Bakkar, S. G. D. de Medina et al., "Mutations in TP53, but not *FGFR3*, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens," *Carcinogenesis*, vol. 26, no. 1, pp. 177–184, 2005.
- [48] A. A. Bakkar, Y. Allory, Y. Iwatsubo et al., "Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of *FGFR3* mutations in bladder urothelial carcinoma," *Molecular Carcinogenesis*, vol. 49, no. 1, pp. 25–31, 2010.
- [49] E. Di Martino, C. G. L'Hôte, W. Kennedy, D. C. Tomlinson, and M. A. Knowles, "Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type-and mutation-specific manner," *Oncogene*, vol. 28, no. 48, pp. 4306–4316, 2009.
- [50] J. M. M. van Oers, C. Adam, S. Denzinger et al., "Chromosome 9 deletions are more frequent than *FGFR3* mutations in flat urothelial hyperplasias of the bladder," *International Journal of Cancer*, vol. 119, no. 5, pp. 1212–1215, 2006.
- [51] A. O. M. Wilkie, "Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations," *Cytokine and Growth Factor Reviews*, vol. 16, no. 2, pp. 187–203, 2005.
- [52] M. Matsumoto, Y. Ohtsuki, K. Ochi et al., "Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions," *Oncology Reports*, vol. 12, no. 5, pp. 967–971, 2004.
- [53] J. J. Gómez-Román, P. Saenz, J. C. González et al., "Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth," *Clinical Cancer Research*, vol. 11, no. 2, pp. 459–465, 2005.
- [54] P. Mhawech-Fauceglia, R. T. Cheney, and J. Schwaller, "Genetic alterations in urothelial bladder carcinoma: an updated review," *Cancer*, vol. 106, no. 6, pp. 1205–1216, 2006.
- [55] J. W. F. Catto, S. Miah, H. C. Owen et al., "Distinct microRNA alterations characterize high- and low-grade bladder cancer," *Cancer Research*, vol. 69, no. 21, pp. 8472–8481, 2009.
- [56] V. Ravery, J. Jouanneau, S. Gil Diez et al., "Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma," *Urological Research*, vol. 20, no. 3, pp. 211–214, 1992.
- [57] D. K. Chopin, J. P. Caruelle, M. Colombel et al., "Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine," *Journal of Urology*, vol. 150, no. 4, pp. 1126–1130, 1993.
- [58] D. Giri, F. Ropiquet, and M. Ittmann, "Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor *FGFR-1* in human prostate cancer," *Clinical Cancer Research*, vol. 5, no. 5, pp. 1063–1071, 1999.
- [59] F. Penault-Llorca, F. Bertucci, J. Adelaide et al., "Expression of FGF and FGF receptor genes in human breast cancer," *International Journal of Cancer*, vol. 61, no. 2, pp. 170–176, 1995.
- [60] F. Yamaguchi, H. Saya, J. M. Bruner, and R. S. Morrison, "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 2, pp. 484–488, 1994.
- [61] N. Turner, A. Pearson, R. Sharpe et al., "FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer," *Cancer Research*, vol. 70, no. 5, pp. 2085–2094, 2010.
- [62] N. C. P. Cross and A. Reiter, "Tyrosine kinase fusion genes in chronic myeloproliferative diseases," *Leukemia*, vol. 16, no. 7, pp. 1207–1212, 2002.
- [63] J. S. Reis-Filho, P. T. Simpson, N. C. Turner et al., "FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas," *Clinical Cancer Research*, vol. 12, no. 22, pp. 6652–6662, 2006.
- [64] K. W. Freeman, B. E. Welm, R. D. Gangula et al., "Inducible prostate intraepithelial neoplasia with reversible hyperplasia

- in conditional FGFR1-expressing mice," *Cancer Research*, vol. 63, no. 23, pp. 8256–8263, 2003.
- [65] K. W. Freeman, R. D. Gangula, B. E. Welm et al., "Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and *in vivo* proliferation," *Cancer Research*, vol. 63, no. 19, pp. 6237–6243, 2003.
- [66] B. E. Welm, K. W. Freeman, M. Chen, A. Contreras, D. M. Spencer, and J. M. Rosen, "Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland," *Journal of Cell Biology*, vol. 157, no. 4, pp. 703–714, 2002.
- [67] V. D. Acevedo, R. D. Gangula, K. W. Freeman et al., "Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition," *Cancer Cell*, vol. 12, no. 6, pp. 559–571, 2007.
- [68] D. C. Tomlinson, F. R. Lamont, S. D. Shnyder, and M. A. Knowles, "Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer," *Cancer Research*, vol. 69, no. 11, pp. 4613–4620, 2009.
- [69] D. C. Tomlinson and M. A. Knowles, "Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer," *American The Journal of Pathology*, vol. 177, no. 5, pp. 2379–2386, 2010.
- [70] S. G. D. de Medina, D. Chopin, A. El Marjou et al., "Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas," *Oncogene*, vol. 14, no. 3, pp. 323–330, 1997.
- [71] D. Ricol, D. Cappellen, A. El Marjou et al., "Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer," *Oncogene*, vol. 18, no. 51, pp. 7234–7243, 1999.
- [72] I. Bernard-Pierrot, A. Brams, C. Dunois-Lardé et al., "Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b," *Carcinogenesis*, vol. 27, no. 4, pp. 740–747, 2006.
- [73] D. C. Tomlinson, C. D. Hurst, and M. A. Knowles, "Knock-down by shRNA identifies S249C mutant *FGFR3* as a potential therapeutic target in bladder cancer," *Oncogene*, vol. 26, no. 40, pp. 5889–5899, 2007.
- [74] J. Qing, X. Du, Y. Chen et al., "Antibody-based targeting of *FGFR3* in bladder carcinoma and t(4;14)-positive multiple myeloma in mice," *The Journal of Clinical Investigation*, vol. 119, no. 5, pp. 1216–1229, 2009.
- [75] J. Martínez-Torrecuadrada, G. Cifuentes, P. López-Serra, P. Saenz, A. Martínez, and J. I. Casal, "Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation," *Clinical Cancer Research*, vol. 11, no. 17, pp. 6280–6290, 2005.
- [76] D. C. Tomlinson, E. W. Baxter, and P. M. Loadman et al., "FGFR1-induced epithelial to mesenchymal transition through MAPK/PLC γ /COX-2-mediated mechanisms," *Plos ONE*, vol. 7, no. 6, 2012.
- [77] J. M. M. van Oers, I. Lurkin, A. J. A. van Exsel et al., "A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine," *Clinical Cancer Research*, vol. 11, no. 21, pp. 7743–7748, 2005.
- [78] T. C. M. Zuiverloon, S. S. Tjin, M. Busstra, C. H. Bangma, E. R. Boevé, and E. C. Zwarthoff, "Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based *FGFR3* mutation assay," *Journal of Urology*, vol. 186, no. 2, pp. 707–712, 2011.
- [79] L. C. Kompier, I. Lurkin, M. N. M. van der Aa, B. W. G. van Rhijn, T. H. van der Kwast, and E. C. Zwarthoff, "*FGFR3*, *HRAS*, *KRAS*, *NRAS* AND *PIK3CA* mutations in bladder cancer and their potential as biomarkers for surveillance and therapy," *PLoS ONE*, vol. 5, no. 11, Article ID e13821, 2010.
- [80] M. J. Roobol, C. H. Bangma, S. el Bouazzaoui, C. G. Franken-Raab, and E. C. Zwarthoff, "Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)," *Urologic Oncology*, vol. 28, no. 6, pp. 686–690, 2010.
- [81] R. R. Serizawa, U. Ralfkiaer, K. Steven et al., "Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of *FGFR3* mutations and hypermethylation events," *International Journal of Cancer*, vol. 129, no. 1, pp. 78–87, 2011.
- [82] L. C. Kompier, M. N. M. van der Aa, I. Lurkin et al., "The development of multiple bladder tumour recurrences in relation to the *FGFR3* mutation status of the primary tumour," *The Journal of Pathology*, vol. 218, no. 1, pp. 104–112, 2009.
- [83] B. W. van Rhijn, T. H. van der Kwast, L. Liu, N. E. Fleshner, P. J. Bostrom et al., "The *FGFR3* mutation is related to favorable pT1 bladder cancer," *The Journal of Urology*, vol. 187, no. 1, pp. 310–314, 2012.
- [84] B. W. G. Van Rhijn, T. C. M. Zuiverloon, A. N. Vis et al., "Molecular grade (*FGFR3/MIB-1*) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer," *European Urology*, vol. 58, no. 3, pp. 433–441, 2010.
- [85] G. Ploussard, H. Soliman, F. Dubosq, P. Meria, J. Verine et al., "The prognostic value of *FGFR3* mutational status for disease recurrence and progression depends on allelic losses at 9p22," *American Journal of Cancer Research*, vol. 1, no. 4, pp. 498–507, 2011.
- [86] M. Mohammadi, S. Froum, J. M. Hamby et al., "Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain," *EMBO Journal*, vol. 17, no. 20, pp. 5896–5904, 1998.
- [87] D. Sarker, R. Molife, T. R. J. Evans et al., "A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors," *Clinical Cancer Research*, vol. 14, no. 7, pp. 2075–2081, 2008.
- [88] M. Mohammadi, G. McMahon, L. Sun et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," *Science*, vol. 276, no. 5314, pp. 955–960, 1997.
- [89] M. Miyake, M. Ishii, N. Koyama et al., "1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (*FGFR3*), inhibits cell proliferation of bladder cancer carrying the *FGFR3* gene mutation along with up-regulation of p27/Kip1 and G₁/G₀ arrest," *Journal of Pharmacology and Experimental Therapeutics*, vol. 332, no. 3, pp. 795–802, 2010.
- [90] F. R. Lamont, D. C. Tomlinson, P. A. Cooper, S. D. Shnyder, J. D. Chester, and M. A. Knowles, "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth *in vitro* and *in vivo*," *British Journal of Cancer*, vol. 104, no. 1, pp. 75–82, 2011.
- [91] H. Greulich and P. M. Pollock, "Targeting mutant fibroblast growth factor receptors in cancer," *Trends in Molecular Medicine*, vol. 17, no. 5, pp. 283–292, 2011.

- [92] M. Harris, "Monoclonal antibodies as therapeutic agents for cancer," *The Lancet Oncology*, vol. 5, no. 5, pp. 292–302, 2004.
- [93] J. L. Martínez-Torrecedrada, L. H. Cheung, P. López-Serra et al., "Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis," *Molecular Cancer Therapeutics*, vol. 7, no. 4, pp. 862–873, 2008.